Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sartorius Stedim Bio    DIM   FR0013154002

News SummaryMost relevantAll newsSector newsTweets 

SARTORIUS STED BIO : Sartorius Stedim Biotech launches initiative to enhance supply chain security

share with twitter share with LinkedIn share with facebook
share via e-mail
04/27/2012 | 05:37pm CEST
Membership in the RX-360 Supply Chain Consortium | Implementation of global guidelines for the use of wooden pallets in its warehouses | Tamper-evident packaging to be implemented for SSB's single-use products to ensure higher level of transportation security

Goettingen, Germany, April 27, 2012 - Sartorius Stedim Biotech (SSB), a leading international pharma and biotech supplier, has substantially extended its supply chain security practices. By launching a comprehensive initiative, SSB is anticipating the emerging requirements of the biopharmaceutical industry for "end-to-end" security across the entire supply chain spectrum, as stressed by leading regulatory bodies like the FDA and related special interest groups. These groups have cited that each link in the supply chain poses a potential threat to a drug's security and that suppliers should be viewed as an extension of a biopharmaceutical manufacturer.

SSB's supply chain security initiative will cover three elements: membership in the RX-360 Consortium, implementation of global guidelines for wooden pallets and tamper-proof packaging. In order to reflect the company-wide importance of supply chain security, SSB has enrolled as a member in the RX-360 Supply Chain Consortium. The purpose of this organization is to enhance the security of the pharmaceutical supply chain by assuring the quality and authenticity of the product suppliers to the drug manufacturer. Sartorius' membership not only enhances the transparency into their quality systems for customers who are also members of Rx360, but should also reduce these customers' audit burden as well.

As a result of the concerns recently raised over the usage of wooden pallets that could potentially cause cross-contamination with chemicals due to precedent treatment, Sartorius Stedim Biotech launched a warehouse campaign as of January 2012. As part of this campaign, all SSB manufacturing sites established warehouse procedures to control wooden pallet use and storage in accordance with the specifications developed by the International Plant Protection Convention (IPPC), which are set forth in greater detail in the International Standards for Phytosanitary Measures (ISPM) 15 "Regulation of Wood Packaging Materials in International Trade."

A further important part of SSB's supply chain security initiative is the implementation of tamper-evident packaging. By using this packaging, in which a special tape indicates whether any packages have been damaged or even opened during transportation, the company has imposed even higher security standards on packaging and thus on the transportation security of its products. These concern consumables, such as presterilized single-use bags and single-use filters, which are used in biopharmaceutical manufacturing and must meet the highest quality criteria. Although SSB does not supply active ingredients or components that become part of the final drug product administered to patients, the company does supply presterilized single-use bag assemblies and filters that come in direct contact with this final product. These SSB products ensure the proper handling and sterilization of the biopharmaceutical product along the entire manufacturing process. For this reason, starting August 1, 2012, SSB will implement tamper-evident packaging for its consumable products to provide added security, as well as ensure proper transportation to their customers.

"As a supplier to the pharma industry, we aim to be ahead of the curve in proactively responding to emerging industry requirements. This is why we will be introducing a supply chain security initiative. Based on this initiative, we intend to offer the highest level of product and transportation security to ensure that our customers receive their product orders in exactly the same perfect quality and safe condition in which they leave our production facilities," commented Thomas Paust, Vice President, Supply Chain Management at Sartorius Stedim Biotech.

This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
02/21 SARTORIUS STEDIM BIO : Resolutions by the Board of Directors
02/08 SARTORIUS STEDIM BIO : 2016 targets fully achieved; strong outlook for 2017
01/25SARTORIUS STEDIM BIOTECH SA : annual earnings release
01/14 SARTORIUS STEDIM BIOTECH : Opens A New Validation Service Laboratory At Its Shan..
2016 SARTORIUS STEDIM BIOTECH : launches two Single-use Sartocon Loop Assemblies
2016 SARTORIUS STEDIM BIO : Biotech Opens New Bioanalytical Testing Laboratory
2016SARTORIUS STEDIM BIOTECH SA : quaterly earnings release
2016 SARTORIUS STEDIM BIO : Profits soar at biotech firm
2016 SARTORIUS STEDIM BIO : Single-Use Bioreactors Market 2016 - GE Healthcare, Therm..
2016SARTORIUS STEDIM BIOTECH SA : half-yearly earnings release
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
03/28DJMEDTRONIC : Files 8K - Entry Into Definitive Agreement
03/28DJMEDTRONIC : Files 8K - Entry Into Definitive Agreement
03/22DJMEDTRONIC : Files 8K - Other Events
03/17DJMEDTRONIC : Less-Invasive Treatment Yielded Similar Outcome as Open-Heart Surger..
03/11DJLUXOTTICA : Smart Glasses Get a Fresh Look -- WSJ
More sector news : Medical Equipment, Supplies & Distribution - NEC
Financials (€)
Sales 2017 1 168 M
EBIT 2017 272 M
Net income 2017 181 M
Debt 2017 4,35 M
Yield 2017 0,71%
P/E ratio 2017 31,38
P/E ratio 2018 27,70
EV / Sales 2017 4,94x
EV / Sales 2018 4,45x
Capitalization 5 764 M
More Financials
Duration : Period :
Sartorius Stedim Bio Technical Analysis Chart | DIM | FR0013154002 | 4-Traders
Full-screen chart
Technical analysis trends SARTORIUS STEDIM BIO
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus HOLD
Number of Analysts 7
Average target price 68,1 €
Spread / Average Target 9,0%
Consensus details
EPS Revisions
More Estimates Revisions
Joachim Kreuzburg Chairman, CEO, CFO & Head-Human Resources
Volker Niebel Executive Director & Executive VP-Operations
Oscar-Werner Reif Executive Director, EVP-Research & Development
Reinhard Vogt Executive Director, EVP-Marketing & Sales Services
Liliane de Lassus Independent Non-Executive Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC PLC13.76%110 524
C R BARD INC11.49%18 113
More Results